M&A Outlook: China Buy side/spin offs & opportunities in South East Asia

M&A Outlook: China Buy side/spin offs & opportunities in South East Asia

We are excited to co-host a webinar with ARC Group, the new owner of NBA member Norient Advisors, on May 25th.
Nordic businesses have a strong commitment in the Greater Chinese and Southeast Asian market in a variety of industries. Despite current challenges related to the Covid-19 pandemic in China, the long-term outlook for China remains positive. Geopolitical challenges also changes the dynamics of cross-border M&A. This Webinar will discuss the opportunities for long-term inorganic growth in Greater China through buy-side, as well as strategic restructuring in China through spin-offs.
As global M&A volumes reached a record USD 5 trillion in 2021, while Chinese outbound volumes has not recovered from 2016 levels, investors are eyeing opportunities in Southeast Asia.
Place: Zoom Link

Registration: Please sign up for your spot by May 24th. Zoom link will be emailed to registered participants prior to webinar.

We are excited to co-host a webinar with ARC Group, the new owner of NBA member Norient Advisors, on May 25th.
Nordic businesses have a strong commitment in the Greater Chinese and Southeast Asian market in a variety of industries. Despite current challenges related to the Covid-19 pandemic in China, the long-term outlook for China remains positive. Geopolitical challenges also changes the dynamics of cross-border M&A. This Webinar will discuss the opportunities for long-term inorganic growth in Greater China through buy-side, as well as strategic restructuring in China through spin-offs.
As global M&A volumes reached a record USD 5 trillion in 2021, while Chinese outbound volumes has not recovered from 2016 levels, investors are eyeing opportunities in Southeast Asia.
Place: Zoom Link
Registration: Please sign up for your spot by May 24th. Zoom link will be emailed to registered participants prior to webinar.

https://norbachina.glueup.cn/event/m-a-outlook-china-buy-side-spin-offs-opportunities-in-s-e-asia-36663/

Continue reading

ARC Group Announces US$15 Million Investment Commitment in Cloudbreak Pharma Inc. (HKEX: 2592)

ARC Group Announces US$15 Million Investment Commitment in Cloudbreak Pharma Inc. (HKEX: 2592)

HONG KONG, 18 June 2026 — ARC Group today announced that it has committed to invest in Cloudbreak Pharma Inc. (HKEX: 2592), a clinical-stage ophthalmology biotechnology company with operations across the United States and China, following the signing of a share subscription agreement through its wholly owned subsidiary ARC Group International Limited. The transaction marks […]
Rising Together | ARC Dragon Boat Team Takes to the Water
Bio Green Med Solution, Inc. Announces Business Combination Agreement to Acquire Future NRG Sdn. Bhd.
Inside ARC Group | University of Nottingham Ningbo China

Please complete this form to download the case study

This field is for validation purposes and should be left unchanged.
*Required before submission